Dr. Grünwald on Dovitinib Versus Sorafenib in mRCC

Viktor Grunwald, MD, PhD
Published: Monday, Sep 30, 2013



Viktor Grünwald, MD, PhD, an attending physician at the Hannover Medical School, discusses a phase III trial that compared dovitinib (FGFR inhibitor) to sorafenib (VEGF inhibitor) for patients with metastatic renal cell carcinoma (mRCC) following prior treatment with one VEGF inhibitor and one mTOR inhibitor.

The primary endpoint of the trial was progression-free survival (PFS) with a total enrollment of 570 patients. Given the large size of the trial, an analysis of overall survival was also plausible, Grünwald states. In the trial, the median PFS was found to be 3.7 months with dovitinib compared to 3.6 months with sorafenib (HR = 0.86; P = .063). The median OS was 11.1 and 11.0 months in the dovitinib and sorafenib, respectively (HR = 0.96; P = .357).

Overall, these results indicate a negative trial, states Grünwald. However, since this is the first phase III trial specifically in the third-line setting, Grünwald believes the results support the use of sorafenib in this space.

<<< View more from the 2013 European Cancer Congress



Viktor Grünwald, MD, PhD, an attending physician at the Hannover Medical School, discusses a phase III trial that compared dovitinib (FGFR inhibitor) to sorafenib (VEGF inhibitor) for patients with metastatic renal cell carcinoma (mRCC) following prior treatment with one VEGF inhibitor and one mTOR inhibitor.

The primary endpoint of the trial was progression-free survival (PFS) with a total enrollment of 570 patients. Given the large size of the trial, an analysis of overall survival was also plausible, Grünwald states. In the trial, the median PFS was found to be 3.7 months with dovitinib compared to 3.6 months with sorafenib (HR = 0.86; P = .063). The median OS was 11.1 and 11.0 months in the dovitinib and sorafenib, respectively (HR = 0.96; P = .357).

Overall, these results indicate a negative trial, states Grünwald. However, since this is the first phase III trial specifically in the third-line setting, Grünwald believes the results support the use of sorafenib in this space.

<<< View more from the 2013 European Cancer Congress


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Key Questions for the Use of Immunotherapy Throughout the Disease Continuum for NSCLC in an Era of Rapid DevelopmentSep 29, 20181.5
Provider and Caregiver Connection™: Addressing Patient Concerns While Managing GlioblastomaSep 29, 20182.0
Publication Bottom Border
Border Publication
x